SMR3B

Across TCGA pan-cancer cohorts, SMR3B RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated SMR3B data layer compared with 3 for mutation status.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SMR3B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SMR3B expression acts as an unfavorable survival marker, although some lineages such as GBM and THCA show a favorable association.

DLBC, READ, and SCLC are the cancer types where SMR3B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Tertile	III,IV	0.131	0.727	.002	54	view →
READ	DFS	Tertile	All	0.255	0.844	.004	54	view →
SCLC	DFS	Tertile	All	0.096	0.576	<.001	45	view →
LUAD	DFS	Tertile	IV	0.047	0.565	<.001	36	view →
LGG	DFS	Tertile	All	0.166	0.461	.009	15	view →
GBM	OS	Tertile	All	0.494	0.238	.019	15	view →
THCA	DFS	Tertile	IV	1.000	0.709	.009	6	view →
SARC	OS	Tertile	All	0.637	0.760	.046	3	view →
UCS	OS	Median	II,III,IV	0.572	0.263	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SMR3B–DLBC (OS)

Open the DLBC breakdown →